Sage Therapeutics Inc
NASDAQ: SAGE
$5.09
+$0.24 (+5.0%)
Real Time Data Delayed 15 Min.
SAGE Articles
Sage Therapeutics shareholders took a bath on Thursday after results from its late-stage major depressive disorder trial came public.
Published:
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Published:
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Published: